{{Rsnum
|rsid=10917670
|Chromosome=1
|position=163063052
|Orientation=plus
|GMAF=0.4357
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{PharmGKB
|RSID=rs10917670
|Name_s=
|Gene_s=RGS4
|Feature=
|Evidence=PubMed ID:18204343
|Annotation=Results from a study in patients with acutely exacerbated schizophrenia suggest that this variant in the RGS4 gene influences clinical manifestations of schizophrenia as well as the treatment response to risperidone.
|Drugs=risperidone
|Drug Classes=
|Diseases=Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA162355848
}}
{{PMID Auto
|PMID=19937977
|Title=Association study of NRG1, DTNBP1, RGS4, G72/G30, and PIP5K2A with schizophrenia and symptom severity in a Hungarian sample
}}
{{PMID Auto
|PMID=19282471
|Title=RGS4 polymorphisms associated with variability of cognitive performance in a family-based schizophrenia sample
|OA=1
}}

{{PMID Auto
|PMID=16905560
|Title=RGS4 mRNA expression in postmortem human cortex is associated with COMT Val158Met genotype and COMT enzyme activity.
}}

{{PMID Auto
|PMID=17092693
|Title=RGS4 is not a susceptibility gene for schizophrenia in Japanese: association study in a large case-control population.
}}

{{PMID Auto
|PMID=18804346
|Title=Interaction between interleukin 3 and dystrobrevin-binding protein 1 in schizophrenia.
|OA=1
}}

{{PMID Auto
|PMID=18834502
|Title=Association of RGS4 variants with schizotypy and cognitive endophenotypes at the population level.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10917670
|overall_frequency_n=59
|overall_frequency_d=128
|overall_frequency=0.460938
|n_genomes=39
|n_genomes_annotated=0
|n_haplomes=46
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}